Patents by Inventor Matthew H. Katcher

Matthew H. Katcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE
    Publication number: 20240109877
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R3, R4A, R4b, and R5, are as defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL.
    Type: Application
    Filed: March 21, 2023
    Publication date: April 4, 2024
    Inventors: Zhiguo Bian, Jason P. Burke, Zhaozhong J. Jia, Xingyu Jiang, Matthew H. Katcher, Venkat Reddy Mali, Violeta L. Marin, Elizabeth L. Noey, Akinori Okano, Alexey A. Rivkin, Spencer O. Scholz, Kevin R. Woller, Xianrui Zhao, Ashley M. Adams, Berenger Biannic, Shahab Mortezaei, Joshua N. Payette, Jeffery A. Zablocki
  • INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING
    Publication number: 20200255423
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Application
    Filed: October 16, 2019
    Publication date: August 13, 2020
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher, Theresa A. Dunstan, David A. Schiedler
  • Inhibitors of tyrosine kinase 2 mediated signaling
    Patent number: 10508113
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: December 17, 2019
    Assignee: AbbVie Inc.
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
  • INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING
    Publication number: 20190276450
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 12, 2019
    Inventors: Maria A. Argiriadi, Eric C. Breinlinger, Ellen Yulin Tsai Chien, Marlon D. Cowart, Kristine E. Frank, Michael M. Friedman, David J. Hardee, J. Martin Herold, Huaqing Liu, Wei Qiu, Marc J. Scanio, Michael R. Schrimpf, Thomas R. Vargo, Stacy A. Van Epps, Matthew P. Webster, Andrew J. Little, Matthew H. Katcher
  • Tyrosine kinase inhibitors
    Patent number: 8222269
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives of formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: July 17, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup
  • Tyrosine kinase inhibitors
    Patent number: 8101603
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: January 24, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup
  • Tyrosine kinase inhibitors
    Publication number: 20090203684
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives of formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: July 6, 2007
    Publication date: August 13, 2009
    Inventors: Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup
  • Tyrosine kinase inhibitors
    Publication number: 20090012076
    Abstract: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Application
    Filed: July 9, 2007
    Publication date: January 8, 2009
    Inventors: Christopher J. Dinsmore, Matthew H. Katcher, Alan B. Northrup